CreatinevsPEA (Palmitoylethanolamide)

Creatine is phosphorylated by mitochondrial creatine kinase (CK-Mt) to form phosphocreatine (PCr), which serves as a rapidly mobilizable high-energy phosphate reserve. When neuronal ATP is consumed during demanding tasks (synaptic vesicle cycling, ion pump activity, action potential propagation), cytosolic brain-type creatine kinase (CK-BB) catalyzes the transfer of the phosphoryl group from PCr to ADP, regenerating ATP within milliseconds — far faster than oxidative phosphorylation or glycolysis can respond. This PCr/CK shuttle also transports high-energy phosphates from mitochondria to distant synaptic sites. Creatine provides direct neuroprotection by stabilizing the mitochondrial permeability transition pore (mPTP), preventing cytochrome c release and downstream apoptotic cascades. It scavenges reactive oxygen species by acting as a direct antioxidant against superoxide and peroxynitrite. Creatine also increases GLUT4 expression in neurons, improving glucose uptake, and upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus, supporting synaptic plasticity and memory consolidation.

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.